Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review

Q3 Materials Science
Mohit Kumar , Ayah R. Hilles , Samah Hamed Almurisi , Amit Bhatia , Syed Mahmood
{"title":"Micro and nano-carriers-based pulmonary drug delivery system: Their current updates, challenges, and limitations – A review","authors":"Mohit Kumar ,&nbsp;Ayah R. Hilles ,&nbsp;Samah Hamed Almurisi ,&nbsp;Amit Bhatia ,&nbsp;Syed Mahmood","doi":"10.1016/j.jciso.2023.100095","DOIUrl":null,"url":null,"abstract":"<div><p>The lung is an attractive target for drug delivery because of the ease of non-invasive administration via inhalation, bypassing metabolism in the liver, direct delivery to the respiratory system for treatment of respiratory diseases, and a large surface area for drug absorption. Nanocarrier systems offer several benefits for pulmonary drug delivery, including uniform drug distribution among alveoli, improved drug solubility, sustained drug release, which reduces the dosing frequency and enhances patient compliance, and potential for cell drug internalization. Nanomedicine is also being utilized to combat emerging infectious illnesses like SARS-CoV, SARS-CoV-2, MERS-CoV, and influenza A/H1N1. This review gives a quick rundown of pulmonary diseases caused by infectious agents such as bacterial, viral, and biological roadblocks that prevent effective treatment of recalcitrant respiratory tract infections. We emphasized and summarized recent efforts to combat these infections using novel inhaled formulation-mediated pulmonary delivery strategies like nanocarriers such as liposomes, polymeric nanoparticles, and SLNs. In addition, we also reviewed the latest findings and advancements regarding the development of inhalable novel formulations that circumvent biological barriers and boost drug bioavailability.</p></div>","PeriodicalId":73541,"journal":{"name":"JCIS open","volume":"12 ","pages":"Article 100095"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCIS open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666934X23000223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Materials Science","Score":null,"Total":0}
引用次数: 2

Abstract

The lung is an attractive target for drug delivery because of the ease of non-invasive administration via inhalation, bypassing metabolism in the liver, direct delivery to the respiratory system for treatment of respiratory diseases, and a large surface area for drug absorption. Nanocarrier systems offer several benefits for pulmonary drug delivery, including uniform drug distribution among alveoli, improved drug solubility, sustained drug release, which reduces the dosing frequency and enhances patient compliance, and potential for cell drug internalization. Nanomedicine is also being utilized to combat emerging infectious illnesses like SARS-CoV, SARS-CoV-2, MERS-CoV, and influenza A/H1N1. This review gives a quick rundown of pulmonary diseases caused by infectious agents such as bacterial, viral, and biological roadblocks that prevent effective treatment of recalcitrant respiratory tract infections. We emphasized and summarized recent efforts to combat these infections using novel inhaled formulation-mediated pulmonary delivery strategies like nanocarriers such as liposomes, polymeric nanoparticles, and SLNs. In addition, we also reviewed the latest findings and advancements regarding the development of inhalable novel formulations that circumvent biological barriers and boost drug bioavailability.

基于微米和纳米载体的肺部给药系统:它们的最新进展、挑战和局限性——综述
肺部是一个有吸引力的药物递送靶点,因为它易于通过吸入进行非侵入性给药,绕过肝脏中的代谢,直接递送到呼吸系统用于治疗呼吸系统疾病,并且具有大的药物吸收表面积。纳米载体系统为肺部药物递送提供了几个好处,包括肺泡中药物分布均匀、药物溶解度提高、药物持续释放(降低给药频率并提高患者依从性),以及细胞药物内化的潜力。纳米医学也被用于对抗新出现的传染病,如严重急性呼吸系统综合征冠状病毒2型、严重急性呼吸综合征冠状病毒和甲型H1N1流感。这篇综述简要介绍了由细菌、病毒和生物屏障等传染源引起的肺部疾病,这些传染源阻碍了顽固性呼吸道感染的有效治疗。我们强调并总结了最近使用新型吸入制剂介导的肺部递送策略来对抗这些感染的努力,如脂质体、聚合物纳米颗粒和SLNs等纳米载体。此外,我们还回顾了可吸入新型制剂的最新发现和进展,这些制剂可以绕过生物屏障,提高药物的生物利用度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCIS open
JCIS open Physical and Theoretical Chemistry, Colloid and Surface Chemistry, Surfaces, Coatings and Films
CiteScore
4.10
自引率
0.00%
发文量
0
审稿时长
36 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信